Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1-specific T cells
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
WT1-specific T cells are an autologous cell therapy designed to treat advanced ovarian, primary peritoneal, and fallopian tube carcinomas. These T cells are engineered or sensitized to specifically recognize and target the Wilms tumor 1 (WT1) protein, which is often overexpressed in various cancers. The therapy aims to induce an immune response against tumor cells expressing WT1, leading to their destruction through a graft-versus-tumor effect. The treatment typically involves collecting the patient's own T cells, sensitizing them to WT1, and then reinfusing them, often after lymphodepletive conditioning with agents like cyclophosphamide and fludarabine.
- Other names
- autologous WT1-specific T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on WT1-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1-specific T cells.